SCHEMBL4760133

SCHEMBL4760133

Cc1cnc(=S)[nH]c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7642901 0.70
SCHEMBL312460 0.70
SCHEMBL28134258 0.62
SCHEMBL27847811 0.57
SCHEMBL10021905 0.56 CCR1 (0.45)
SCHEMBL31255 0.56
SCHEMBL2645682 0.53
SCHEMBL4436936 0.52
SCHEMBL6886877 0.52
SCHEMBL14410866 0.52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12351583-B2 Triazolopyrimidines based on thymine nucleobase and methods for producing them CHEMITERAS, INC. (JP) 2025-07-08 US disclosed
CN-113692306-B Triazolopyrimidines based on thymine nucleobases and methods for their manufacture 泰拉强石株式会社 2024-06-21 CN disclosed
US-20220194950-A1 TRIAZOLOPYRIMIDINES BASED ON THYMINE NUCLEOBASE AND METHODS FOR PRODUCING THEM TERA STONE CO., LTD (JP) 2022-06-23 US disclosed
EP-3950064-A1 THYMINE NUCLEOBASE-BASED TRIAZOLOPYRIMIDINES AND PRODUCTION METHOD THEREFOR Tera Stone Co., Ltd (JP) 2022-02-09 EP disclosed
WO-2020204024-A1 THYMINE NUCLEOBASE-BASED TRIAZOLOPYRIMIDINES AND PRODUCTION METHOD THEREFOR テラ・ストーン株式会社 2020-10-08 WO disclosed
US-8835625-B2 Propargyl substituted nucleoside compounds and methods APPLIED BIOSYSTEMS, LLC (US) 2014-09-16 US disclosed
US-8835625-B2 Propargyl substituted nucleoside compounds and methods APPLIED BIOSYSTEMS, LLC (US) 2014-09-16 US disclosed
US-8344118-B2 Preparation and isolation of 5′ capped MRNA APPLIED BIOSYSTEMS, LLC (US) 2013-01-01 US disclosed
US-8344118-B2 Preparation and isolation of 5′ capped MRNA APPLIED BIOSYSTEMS, LLC (US) 2013-01-01 US disclosed
US-20120309953-A1 Propargyl Substituted Nucleoside Compounds and Methods Life Technologies Corporation (US) 2012-12-06 US disclosed
US-7998706-B2 Pyrimidine nucleobases APPLIED BIOSYSTEMS, LLC (US) 2011-08-16 US disclosed
US-20100304389-A1 Preparation And Isolation of 5' Capped mRNA Life Technologies Corporation (US) 2010-12-02 US disclosed
US-20100304389-A1 Preparation And Isolation of 5' Capped mRNA Life Technologies Corporation (US) 2010-12-02 US disclosed
US-20100113759-A1 PROPARGYL SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS Life Technologies Corporation (US) 2010-05-06 US disclosed
US-20100113759-A1 PROPARGYL SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS Life Technologies Corporation (US) 2010-05-06 US disclosed
WO-2009058911-A2 PREPARATION AND ISOLATION OF 5' CAPPED MRNA APPLIED BIOSYSTEMS INC. (US) 2009-05-07 WO disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP disclosed